Search Results

You are looking at 151 - 160 of 804 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

Maria Kathleen Riley, Alex Wong, Songzhu Zhao, Jing Wang, Vince Esguerra, Mingjia Li, Kari Kendra, Gabrielle Lopez, Carolyn Presley, Lai Wei, Dwight Owen, and Kevin Ho

Rationale : Immune checkpoint inhibitors (ICIs) are the mainstay of treatment for various metastatic tumors. Pneumonitis is a potentially fatal side effect of ICIs. However, there is little data regarding risk factors for developing ICI

Full access

Qingqing Zhou, Chenchen Zhu, Zhen Shen, Jing Zhu, Tianjiao Zhang, Min Li, Jiwei Qin, Lili Qian, Chuan Chen, Hanyuan Liu, Zhihao Xu, Dabao Wu, Björn Nashan, and Ying Zhou

Objective: To assess the incidence and the risk factors of venous thromboembolism (VTE) in patients with epithelial ovarian carcinoma (EOC) during perioperative period. Methods: A retrospective analysis was conducted on the patients with

Full access

Jung Julie Kang, Hannah Verma, Kaveh Zakeri, Huili Wang, Dan Fan, Ming Fan, Anna Lee, Sarin Kitpanit, Linda Chen, Yao Yu, C. Jillian Tsai, Sean McBride, Nadeem Riaz, Daphna Gelblum, Alan S. Ho, Eric Sherman, Lara Dunn, Jay O. Boyle, Richard J. Wong, Ian Ganly, and Nancy Y. Lee

had close or positive margins (84%), 14% had recurrent disease after prior surgery, and 27% received concurrent chemotherapy. Multiple risk factors (MRF) were defined as two or more of the following: T3/T4 stage, high-grade, LVI, PNI, or close

Full access

Alexa Henderson, Stacy Smrz, Michelle Lightfoot, Jason Benedict, Erin Bishop, Glenn Boyles, Alexandra Stiles, and Kristin Bixel

Background: While women undergoing treatment for gynecologic malignancies have multiple risk factors for osteoporosis and fracture, little is understood about the risk of fracture in this population and therefore women may not undergo recommended

Full access

Ahmad Raza, Muhammad Umair Atiq, Steven Qian Zhang, Vincent Chan, Ahmad Arslan, and Christian Fidler

most susceptible period being between 6 months to 1 years after starting immunotherapy (75%). Among patients with pneumonitis, underlying structural lungs disease seems to be a prominent risk factor (75% vs 66%). Conclusion: Pembrolizumab and

Full access

Manal AL Al Humaid, Mohammed Amin, Ahmed Al Qudaimat, Lolwah Alriyees, Carmen Vasilescu, and Hussam Shehata

with coping strategies. Eventually, making the move towards tailored medical service. Keywords: Male breast cancer, Saudi Arabia, embarrassment, psychological impact, risk factors, awareness

Full access

NCCN Guidelines Insights: Survivorship, Version 2.2020

Featured Updates to the NCCN Guidelines

Crystal S. Denlinger, Tara Sanft, Javid J. Moslehi, Linda Overholser, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Tracey O’Connor, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

cardiomyopathy, hypertension, hyperlipidemia, cardiac arrhythmia, myocardial infarction, and cerebrovascular accidents. 11 – 17 In addition, shared risk factors for both cancer and CVD likely contribute to the development of CVD and structural heart disease or

Full access

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic

factors for basal and squamous cell cancers associated with inadequate treatment of primary tumors (i.e., risk factors associated with recurrence and metastasis). For each parameter, the group agreed on specific criteria to indicate when a given tumor is

Full access

Jason T. Lee and Maziyar A. Kalani

anticardiolipin antibodies . Neth J Med 1997 ; 50 : 85 – 87 . 9. Martinelli I Cattaneo M Taioli E . Genetic risk factors for superficial vein thrombosis . Thromb Haemost 1999 ; 82 : 1215 – 1217 . 10. de Godoy JM Batigalia F Braile DM

Full access

Marcy Neuburg

transplantation: the Australian experience . Cancer 1999 ; 85 : 1758 – 1764 . 8. Fortina AB Caforio AL Piaserico S . Skin cancer in heart transplant recipients: frequency and risk factor analysis . J Heart Lung Transplant 2000 ; 19 : 249 – 255